These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28810323)

  • 21. Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
    Wu L; Li X; Chang C; Xu F; He Q; Wu D; Zhang Z; Su J; Zhou L; Song L; Chao X; Zhao Y
    Leuk Lymphoma; 2016; 57(6):1367-74. PubMed ID: 26397697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
    Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
    [No Abstract]   [Full Text] [Related]  

  • 23. [Comparation of Clinical Efficacy between Two Regimens of Preexcitation Chemotherapy for MDS-RAEB Patients].
    Pan PJ; Luo ZQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):515-519. PubMed ID: 30998163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
    Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
    Xuan L; Dai M; Jiang E; Wang Y; Huang F; Fan Z; Xu N; Nie D; Liang X; Chen H; Ye J; Shi P; Liu H; Jin H; Lin R; Yan C; Zhang Y; Sun J; Han M; Liu Q
    Lancet Haematol; 2023 Mar; 10(3):e178-e190. PubMed ID: 36702138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival Benefit and Efficiency of Low Dose Decitabine With CEG Regimen Compared to Decitabine Alone in the Elderly MDS - A Multicenter, Retrospective Study.
    Ma J; Liang Y; Wu M; Xie M; Hua J; Hu Y; Yang R; Zou Z; Wang X; Xu Y; Wang X; Ye X; Xie Y
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):e792-e800. PubMed ID: 34226168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
    Sun Y; Xu Y; Wu D; Shen H; Yang Z; Qiu H; Chen S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2015 Dec; 36(12):1025-30. PubMed ID: 26759106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical efficacies and safety of HAG regimen for patients with high-risk myelodysplastic syndromes: a multicentre study].
    Liu H; He GS; Wu DP; Sun AN; Shao ZH; Qian SX; Xiao ZJ; Ma J; Wang SY; Xu XP; Liu T; Jin J; Chen ZC; Fang MY; Chen BA; Xu LP; Shen ZX; Ruan CG
    Zhonghua Yi Xue Za Zhi; 2012 Mar; 92(10):689-91. PubMed ID: 22781297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic effect of decitabine combined with HAG in acute myeloid leukemia: a retrospective case-control analysis.
    Yi K; Xu SH; Cheng H; Chen SY; Jin T
    Eur Rev Med Pharmacol Sci; 2023 Dec; 27(23):11334-11339. PubMed ID: 38095382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
    Xu J; Xu CG; Liu T; Xiang B; Chang H; He C
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):129-32. PubMed ID: 19292062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
    Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting.
    Ren Y; Jiang H; Shi F; Ye L; Luo Y; Zhou X; Mei C; Ma L; Xu W; Lin P; Hu C; Jin J; Tong H
    Leuk Lymphoma; 2019 Jul; 60(7):1731-1739. PubMed ID: 30616472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
    Wang H; Bai J; Pei Z; Zhang B; Wang J; Lian X; Song Q
    Medicine (Baltimore); 2020 Nov; 99(47):e23265. PubMed ID: 33217852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
    Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
    Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes.
    Ferrara F; Leoni F; Pinto A; Mirto S; Morra E; Zagonel V; Mele G; Ciolli S; Magrin S; Montillo M
    Cancer; 1999 Nov; 86(10):2006-13. PubMed ID: 10570425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of the impact of decitabine treatment cycles on efficacy and safety in patients of myelodysplastic syndrome-refractory anemia with excess blasts].
    Luo XP; Xu ZF; Qin TJ; Zhang Y; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Li B; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):870-875. PubMed ID: 27801319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E
    Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical efficacy of decitabine plus improved CAG chemotherapy and haplo-identical donor peripheral lymphocyte infusion regimen on elderly patients with high risk myelodysplastic syndrome and acute myeloid leukemia].
    Dou LP; Jing Y; Wang QS; Mei JH; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):662-6. PubMed ID: 23815918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
    Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.